M
Magenta Medical
Health Tech & Medtech · Tel Aviv-Yafo, Israel · Founded 2012
Magenta Medical has developed a temporary venous catheter-based therapy MoreLess
Magenta Medical develops advanced medical devices focused on providing temporary support for patients with severe heart conditions. The company specializes in two main products: the percutaneous Left Ventricular Assist Device (pLVAD) and the Transcatheter Renal Venous Decongestion System. The pLVAD is a next-generation, low-profile arterial pump designed to offer temporary support for patients undergoing high-risk coronary interventions and those suffering from cardiogenic shock. The Transcatheter Renal Venous Decongestion System is a venous pump aimed at treating hospitalized patients with acutely decompensated heart failure by reducing renal venous pressure and decompressing the kidneys.
Magenta Medical primarily serves hospitals and healthcare providers dealing with critical heart failure cases. Operating in the medical device market, the company employs a business model that includes the development, manufacturing, and sale of its specialized pumps. Revenue is generated through direct sales to healthcare institutions and partnerships with medical distributors.
Keywords: heart failure, pLVAD, arterial pump, venous pump, coronary interventions, cardiogenic shock, renal venous pressure, decompensated heart failure, medical devices, healthcare providers.
Company overview
Magenta Medical company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 118
- Open positions
- 7
- Dealroom signal
- 54.3
Valuation & funding
Magenta Medical funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2024 | $105M | $420M | NEA · OrbiMed · Viking Global Investors · JVC Investment Partners | ↗ |
| LATE VCOther financing | May 2023 | $55M | $220M | Pitango Venture Capital · NEA · ALIVE Israel HealthTech Fund · OrbiMed | ↗ |
| LATE VCOther financing | Jul 2019 | $10M | $40M | Pitango Venture Capital · Jacques R. Seguin · NEA | ↗ |
| SERIES BOther financing | Sep 2017 | $15M | $60M | ABIOMED, LTD. · Pitango Venture Capital · Abiomed · Jacques R. Seguin | ↗ |
| SEEDOther financing | Dec 2012 | $4M | $16M | Pitango Venture Capital | — |
Growth signals
Magenta Medical website traffic
Latest recorded traffic for Magenta Medical is 3.2K monthly website visits, up 332.4% over the last three months. Magenta Medical's team grew 11.3% over the past year.
Hiring
Open positions at Magenta Medical
Current openings linked to this company in Dealroom.
Comparisons
Magenta Medical compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Magenta Medical's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Magenta Medical has talent and traffic
team presence
In the news
Latest news about Magenta Medical
Recent press, funding announcements, and product moves mentioning Magenta Medical — open to read from the original sources.
Market sentiment
What the market is saying about Magenta Medical
An AI-synthesized read of the highest-engagement posts about Magenta Medical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Magenta Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.